Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice
Rajamäki, Aino; Sorigue, Marc; Prusila, Roosa E I; Kuusisto, Milla E L; Kuitunen, Hanne; Jantunen, Esa; Mercadal, Santiago; Turpeenniemi-Hujanen, Taina; Sancho, Juan-Manuel; Sunela, Kaisa; Kuittinen, Outi (2024-05-06)
Rajamäki, Aino
Sorigue, Marc
Prusila, Roosa E I
Kuusisto, Milla E L
Kuitunen, Hanne
Jantunen, Esa
Mercadal, Santiago
Turpeenniemi-Hujanen, Taina
Sancho, Juan-Manuel
Sunela, Kaisa
Kuittinen, Outi
Medical Journals Sweden
06.05.2024
Rajamaki, A., Sorigue, M., Prusila, R. E., Kuusisto, M. E., Kuitunen, H., Jantunen, E., Mercadal, S., Turpeenniemi-Hujanen, T., Sancho, J.-M., Sunela, K., & Kuittinen, O. (2024). Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice. Acta Oncologica, 63(1), 267–272. https://doi.org/10.2340/1651-226X.2024.24377
https://creativecommons.org/licenses/by/4.0/
© 2024 The Author(s). Published by MJS Publishing on behalf of Acta Oncologica. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
https://creativecommons.org/licenses/by/4.0/
© 2024 The Author(s). Published by MJS Publishing on behalf of Acta Oncologica. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
https://creativecommons.org/licenses/by/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202405083187
https://urn.fi/URN:NBN:fi:oulu-202405083187
Tiivistelmä
Abstract
Background:
The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies.
Patients and methods:
We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1–2 FL between 1997 and 2016 in nine institutions were included.
Results:
The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7–9.3 years), 4.2 years (95% CI: 2.8–5.6 years) and 2.2 years (95% CI 1.7–2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset.
Interpretation:
With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.
Background:
The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies.
Patients and methods:
We set out to determine progression-free survival (PFS) after front line, second line, and third line of therapy on the basis of relevant biological characteristics and therapeutic choices. Patients (n = 743, 51% females, median 60 years old) diagnosed with grade 1–2 FL between 1997 and 2016 in nine institutions were included.
Results:
The median PFS1, PFS2, and PFS3 were 8.1 years (95% confidence interval [CI]: 7–9.3 years), 4.2 years (95% CI: 2.8–5.6 years) and 2.2 years (95% CI 1.7–2.8 years). We found longer PFS1 for (1) females, (2) younger age, (3) lower-risk follicular lymphoma international prognostic index (FLIPI), (4) standard intensity (over low intensity) regimens and (5) immunochemotherapy strategies and (6) maintenance rituximab. We found a shorter PFS2 for patients who received front-line immunochemotherapy. Older age at diagnosis correlated with a shorter PFS3. Intensity of front-line chemotherapy, maintenance, or POD24 status did not correlate with PFS2 or PFS3 in this dataset.
Interpretation:
With current immunochemotherapy strategies, the natural course of FL is characterized by shorter-lasting remissions after each relapse. It will be interesting to see whether new therapies can alter this pattern.
Kokoelmat
- Avoin saatavuus [32523]